Liver cirrhosis is a disease characterized by the loss of functional liver mass. Physiologicallybased pharmacokinetic (PBPK) modeling has been applied to interpret and predict how the interplay among physiological changes in cirrhosis affects pharmacokinetics. However, previous PBPK models under cirrhotic conditions were developed for permeable cytochrome P450 substrates and do not directly apply to substrates of liver transporters. This study characterizes a PBPK model for liver transporter substrates in relation to the severity of liver cirrhosis. A published PBPK model structure for liver transporter substrates under healthy conditions and the physiological changes reported for cirrhosis are combined to simulate pharmacokinetics of liver transporter substrates in patients with mild and moderate cirrhosis. The simulated pharmacokinetics under liver cirrhosis reasonably approximate observations. The major contributions This analysis includes the meta-analysis to obtain system-dependent parameters in cirrhotic patients, and a top-down approach to improve understanding of effect of cirrhosis on transporter-mediated drug disposition under cirrhotic conditions.This work can be useful in understanding the change of liver transporter activity due to cirrhosis, and predicting pharmacokinetics of liver transporter substrates under cirrhotic conditions.
INTRODUCTION
Liver cirrhosis is a progressive disease characterized by loss of liver function associated with the morphological and physiological changes. The disease progression is usually classified using the Child-Pugh Grades (CP-A (mild), CP-B (moderate), and CP-C (severe)) (1) . Physiological changes under pathological condition include loss of functional liver size, decreased cytochrome P450 (CYP) expression, reduced glomerular filtration rate (GFR), and altered cardiac output, hepatic blood flow, hematocrit, and plasma albumin and α1-acid glycoprotein concentrations (1, 2) . The changes may affect systematic and tissue exposure of drugs administered to the patient.
Under these pathological conditions, it is necessary to assess drug pharmacokinetics to evaluate potential risk and altered pharmacodynamic effects.
Compared with empirical pharmacokinetic models, physiologically physiologically-based pharmacokinetic (PBPK) modeling explicitly incorporates physiological information, and can deconvolute multiple mechanisms controlling drug pharmacokinetics (3) . As such, PBPK analysis can be invaluable to gain insights into the impact of physiological changes on the pharmacokinetics under disease conditions. PBPK models have been reported in previous publications to predict the pharmacokinetics in patients with liver impairment (4) (5) (6) . With a "well-stirred" liver model (7) , these PBPK models successfully extrapolate pharmacokinetics from healthy individual to patients, in terms of adequately describing the observed plasma pharmacokinetics under different disease conditions. In addition to the lipophilic compounds that have been mechanistically modeled (4) (5) (6) , several groups also have investigated the pharmacokinetics of liver transporter substrates under mild and moderate liver cirrhosis conditions, prompted by the fact that these compounds are mainly eliminated hepatically (8) (9) (10) (11) (12) . In addition, some liver transporter substrates are developed to treat diseases associated with liver cirrhosis. For example, bosentan (13) is a dual endothelin receptor antagonist used in the treatment of pulmonary artery hypertension, which has a higher prevalence in more severely cirrhotic patients (14) . Repaglinide treats type 2 diabetes (15) . In a populationbased diabetes study, cirrhosis was the fourth leading cause of death and accounted for 4.4% of diabetes-related deaths; diabetes is also the most common cause of liver disease in the U.S. (16) .
To date, these compounds have not been modeled under cirrhotic conditions using a PBPK approach, and models for highly permeable compounds cannot be reasonably expected to describe the pharmacokinetics of liver transporter substrates (17) .
PBPK models for liver transporter substrates have been developed previously, where the distribution of the compounds is modeled as permeability limited in order to incorporate both passive diffusion and active uptake due to transporter activity (18) (19) (20) (21) . In this study, we extended published PBPK models (18) (19) (20) (21) to extrapolate pharmacokinetics from healthy individuals to patients with cirrhosis. The model structure for liver transporter substrate disposition in healthy individuals was combined with adjustments of physiologic parameters reported in the models for high permeable compounds under cirrhotic conditions. This work provides a updates current understanding of the effect of liver cirrhosis on system parameters, including transporter processes, and has potential usefulness in the individualized dosage adjustment of practical approach to predict systemic and potentially liver exposure of the liver transporter substrates under disease conditions.
METHODS

Model structure
The published PBPK model structure for organic anion transporting polypeptides (OATP) substrates incorporating hepatic uptake clearance (CLact), passive diffusion (CLpass), metabolic (CLmet), and biliary (CLbile) clearances (19) is applied for bosentan, olmesartan, repaglinide, and valsartan. The model assumes no active basolateral efflux due to challenges of estimating this activity, although it has been described for at least rosuvastatin (22, 23) . Enterohepatic recirculation of the parent compound is not modeled for olmesartan and valsartan due to its limited impact on the plasma pharmacokinetic simulations performed with current model (data not shown). For telmisartan, additional model components for deconjugation of glucuronide metabolite and enterohepatic recirculation of parent were added to the PBPK model to account for the long half-life and large apparent volume of distribution observed in clinical data as described before (24) .
First order absorption kinetics with absorption rate (ka), fraction absorbed (Fa) and assuming no intestinal metabolism or transport (i.e., Fg = 1) are used to describe plasma data after oral dosing of repaglinide and telmisartan (24) . Because the first order absorption cannot adequately describe the plasma concentration-time curves after oral dosing of bosentan and valsartan, a saturable absorption model with maximum absorption rate (Vmax), and Michaelis-Menten saturation constant (Km) (25) is used for these two compounds (other empirical absorption models described in (25) including zero-order model, sequential independent zero and first order model, sequential linked zero and first order model, and model with delayed absorption were also tested, but these model did not improve the fitting).
The model is implemented in MATLAB (version 2010b). The fitted parameters are estimated by minimizing the squared error between log10 transformed data and simulations, using the pattern search optimizer in the MATLAB Global Optimization Toolbox.
Local sensitivity analysis
Local sensitivity analyses of the area under curve (AUCplasma, 0 − t and AUCliver, 0 − t) are conducted as described previously where each parameter (for healthy individual) is raised by 1% with respect to its value in the simulations (18) . Sensitivity coefficients are normalized to both the parameter value and the model output. To keep the blood flow balanced, when the blood flow to any other organ is increased, the lung blood flow and the cardiac output will be raised accordingly. Similarly, if the lung blood flow or the cardiac output is raised, blood flow in all other organs will be increased. If liver arterial blood, gut blood, or spleen blood flow is raised, both lung blood flow and liver venous blood flow will be increased, and vice versa. To analyze the sensitivity to the liver mass (for healthy individual the functional liver mass is the same as the physical liver mass), CLpass, CLact, CLmet, and CLbile are raised 1% together with the liver volume. Only parameters with normalized sensitivity coefficients greater than 0.3 or less than −0.3 are reported.
Physiological parameters for cirrhosis
Parameters Meta-analysis. We used the same source literature reporting changes for physiological parameter values as published before (5) . For the functional liver size analysis, only datasets classified using Pugh-Child system are selected. Studies using functional assays (e.g. galactose elimination capacity or hepatic sorbitol clearance), are not included because the data may be confounded by blood flow, or the expression level of metabolic enzymes. The physiological changes associated with liver cirrhosis are represented as the ratios of mean reported values between the disease group and healthy group (except for RB/P). To estimate the population mean of the ratios based on the individual studies, one could pool the measured physiological parameter values, and take the ratios between population means of healthy and cirrhosis groups.
However, the measurement techniques for these parameters are different from study to study, as such it may not be proper to pool these measurements directly. To bypass this challenge, instead of pooling the measurements, we take the ratios of individually reported values, and pool the ratios to estimate the population mean of the ratios.
The ratios are calculated as
where xcirrohsis and xhealthy represent the reported sample mean values for cirrhosis group and healthy group in the study i. The standard error (SE) of the ratios in each individual study is calculated through the propagation of uncertainty: 
The sample standard deviations of the ratios (SDi) are calculated using the same approach. The population mean value (WX) and population standard deviations (SD) of ratios from N individual studies are estimated as follows using the reciprocal of standard error-weighted mean (26) and pooled variance (27) .
where ni typically indicates the sample size in the study i. In the clinical studies, ni was reported for the participants in the healthy and the cirrhotic groups. However, in our analysis which relies on ratios, we approximated ni as the average number of healthy and cirrhotic participants in each study.
Plasma fraction unbound. Plasma fraction unbound (fu,p) of bosentan, repaglinide, telmisartan, and valsartan have been reported for healthy individuals (18, 24) . The in-house value of fu,p for olmesartan is used. Assuming the unbound albumin concentration (Calbumin) is approximately equal to the total albumin concentration (Table 3) , fu,p values for patients with liver cirrhosis are estimated based on a previously published approach (28) .
, , 
Blood to plasma ratio. Blood to plasma ratio (RB/P) is defined as
where C and V represent concentration and volume; B, E, and P represent blood, erythrocyte, and plasma; and HCT represents hematocrit ( Table 3 ). The reported RB/P values for bosentan, repaglinide, and valsartan in healthy individuals are 0.48, 0.48, 0.55, and 0.545 (18) , which would result in CE/CP less than zero. Hence, for these compounds, CE/CP is fixed at zero, indicating very limited accumulation of these compounds in the erythrocyte. RB/P of olmesartan is not reported, however the compound does not penetrate red blood cells (29), hence CE/CP is also fixed at zero. For telmisartan, CE/CP is reported to be 0.5 (30) , and assumed to be constant and independent of disease conditions.
Tissue to plasma partition coefficient. The tissue to plasma partition coefficients (Kp) for nonliver tissues are calculated using in silico method reported previously (31) under different disease conditions. In the Kp calculation, fu,p and RB/P values are calculated above, pKa and logD7.4
values are in Table 1 adjusted using values given in Table 3 . Blood flows in other tissues are also adjusted accordingly such that the sum of blood flow fractions contributed by the tissues is 1.
Renal clearance. Renal clearance (CLR) of prodrug of olmesartan (olmesartan medoxomil)
under healthy and cirrhosis conditions has been reported (29) . Since CLR has not been reported for olmesartan, we assume that CLR values of olmesartan and its prodrug are the same considering the fast conversion from prodrug to olmesartan in the human body (29) . There is no reported CLR of valsartan under conditions of cirrhosis but only for healthy individuals (32), hence the ratios of valsartan CLR between healthy and cirrhotic conditions are estimated as the weighted mean values of rosuvastatin and olmesartan (0.85 and 0.79 for CP-A and B groups, Supplemental Materials) (11, 29) . Alternatively, assuming changes in CLR in cirrhosis are similar to those for is proportional to glomerular filtration rate (GFR) and kidney transporters are not affect by cirrhosis, valsartan CLR under cirrhotic conditions can be predicted using ratios for GFR changes in the previous meta-analysis (0.70 and 0.58 for CP-A and B in (5)). However, such approach leads to greater changes oin CLR than the observed values infor rosuvastatin and olmesartan studies (11, 29) . The pharmacokinetics of rosuvastatin in healthy (11) and liver cirrhosis individuals (11) have been published, however under cirrhotic conditions only derived pharmacokinetic parameters but not concentration-time course are reported. As such, rosuvastatin is not included in this study, because of the additional challenge in estimating absorption and hepatic clearance without time course data. We assume there is no renal excretion for the other three compounds (18, 24) . The unbound renal clearance (CLR,u) is calculated using reported or estimated clinical renal clearance assuming well-stirred conditions as described before (18):
where Qrenal,blood is renal blood flow.
Hepatic clearance. CLpass and CLact of bosentan, repaglinide, and valsartan, CLmet of bosentan and repaglinide, as well as CLbile of olmesartan and valsartan, for healthy individuals are estimated by fitting the model to the observed plasma concentration time profiles after intravenous dosing (11, 13, 15, 32) . CLmet of olmesartan and valsartan, and CLbile of repaglinide are fixed at zero (19, 29) . CLbile of bosentan is fixed at a previously predicted value using sandwich-cultured human hepatocyte (SCHH) (19 Passive permeability of the compound is assumed be independent of the disease status, hence
CLpass under cirrhosis condition is assumed to be only affected by the functional liver mass.
pass ,cirrhosis pass,healthy liver mass
where Rliver mass is the fraction of the functional liver size in healthy control.
CLmet under liver cirrhosis conditions is assumed to be decreased due to both reduced functional liver mass and the reduced metabolic enzyme activity as described previously (4, 5). 
 
where Fenzyme is the fraction of the total metabolism contributed by each metabolic enzyme involved in the hepatic metabolism; Rmetabolism is the ratio of metabolic enzyme activity between the diseased group and the healthy control, i represents each metabolic enzyme, and n is the number of metabolic enzymes. According to previous HLM studies, 60% of dosed bosentan is metabolized through CYP3A4, and the remaining 40% metabolized through CYP2C9 (33), while 63% of repaglinide is metabolized by CYP2C8, 18% by CYP3A4, and 19% by UDPglucuronosyltransferase (UGT) (34) . Telmisartan is metabolized exclusively by UGT (35) . We used reported Rmetabolism of CYP3A4, CYP2C8 and CYP2C9 activity in CP-A, CP-B, and CP-C patients (5). The UGT activity is assumed to be not affected by liver cirrhosis as suggested by a previous study (36 
where Ftransporter is the fraction of each transporter made to CLact (or CLbile), and Rtransporter is the ratio of transporter activity between the diseased group and the healthy control. Rtransporter has been reported using mRNA measurements but the diseased individuals were not assessed based on Child-Pugh classification system (Table 3 ) (37, 38) , hence in the prospective predictions (Method 1), we assume the three disease groups have the same Rtransporter and standard deviation.
Ftransporter has been reported for olmesartan (OATP1B1, 0.53; OATP1B3, 0.47; no OATP2B1 and NTCP uptake (39, 40)) but not for the other four compounds, hence for other compounds
Ftransporter are generated randomly from a uniform distribution.
Assuming liver cirrhosis has a unique similar impact on all uptake (or biliary efflux) transporters,
Rtransporter values of CP-A and CP-B are estimated by fitting observed concentration-time courses
of patients while fixing other parameters at their mean values in Table 3 (Method 2). Because the current simulations are not sensitive to CLbile as they are to CLact (Table 2) , a similar assumption is also made on biliary transporters, although this assumption is not entirely consistent with mRNA data (Table 3 ). The uncertainty of fitted parameters are approximated by residual bootstrap (19) . The pharmacokinetics of repaglinide were waswere reported as the average value of 9 CP-B and 3 CP-C patients (9) . Studies for the other four compounds did not include CP-C individuals. We assumed Rtransporter of CP-C patients has the same value as that of CP-B patients, because adding separated parameters for CP-C patients does not improve the fitting (data not shown).
The previously reported fractions unbound in liver tissue (fu,liver) (19, 24) are used for healthy individuals and the two cirrhosis groups, assuming fu,liver is not affected by the liver cirrhosis.
Since there is no published value of fu,liver for olmesartan, it is predicted from fu,p as described previously (18) . 
Drug absorption. The absorption parameters ka (or
Simulations of pharmacokinetics under liver cirrhotic conditions
Assuming all parameters are independent of each other and follow normal distributions, the values of albumin concentrations as the fraction of healthy control are randomly generated from a normal distribution with mean and standard deviation in 
RESULTS
Published plasma time course data in healthy individuals and cirrhotic patients for liver transporter substrates bosentan (12, 13) , olmesartan (29) , repaglinide (9, 15) , and telmisartan (10, 30) , valsartan (8, 32) were analyzed. The values of compound-specific parameters for healthy individuals are given in Table 1 (except for tissue-plasma partition coefficients (Kp) for non-liver tissues, shown in the Supplemental Materials). With fitted hepatic clearances and oral absorption parameters, the simulated bosentan, olmesartan, repaglinide, telmisartan, and valsartan plasma concentrations can reasonably match the observations from healthy individuals ( Figure 1 ).
The local sensitivity analysis (Table 2) indicates that AUCplasma is in general sensitive to parameters including plasma fraction unbound (fu,p), blood to plasma ratio (RB/P), hepatic active uptake (CLact), passive diffusion (CLpass), metabolic (CLmet) (or biliary (CLbile)) clearances, the functional liver tissue volume (Vlt), liver venous blood flow (Qhv), cardiac output, and fraction absorbed (Fa). These results are consistent with published findings (18, 24) . The AUCliver of most compounds is sensitive to liver tissue fraction unbound (fu,liver), CLmet (or CLbile), Vlt, and Fa (Table 2) .
To prospectively predict pharmacokinetics under liver cirrhosis conditions, these parameters with high sensitivity coefficients are adjusted. The ratios (and the standard deviations of ratios)
between healthy individuals and liver cirrhosis patients (CP-A, CP-B, and CP-C) are estimated from published studies (Table 3) . We used published mRNA data (37, 38) to estimate the ratios of transporter activities (Rtransporter) between healthy individuals and CP-A (and CP-B)diseased groups (Method 1). Unfortunately, these data are not classified based on Child-Pugh system so.
As such, for liver transporter activity, the same ratio is applied to different all cirrhotic groups (Table 3) . The parameter values under cirrhosis are predicted as the products of healthy values (Table 1 ) and the ratios (Table 3 ). The fraction each transporter contributes to hepatic uptake or biliary efflux is unknown except for olmesartan uptake (39, 40) , hence is randomly generated in the simulations. Assuming parameters are independent of each other and follow normal distributions with means and standard deviations given in Table 3 , 1000 simulated plasma concentration-time profiles are generated for each compound. The averaged simulations for liver cirrhosis patients, 2.5 and 97.5 percentiles are superimposed on the observations (Figure 2 ). The observed and predicted AUCplasma with 95% prediction intervals are reported in Table 4 .
The predictions more reasonably match observations from CP-A groups than CP-B groups. This is probably due to mis-prediction of liver transporter activity under CP-B conditions using mRNA data.
Assuming in liver cirrhosis has the same impact on all uptake (or efflux) transporters are similarly affected within a grade but differences exist between grades, we estimated Rtransporter by simultaneously fitting observed pharmacokinetics of the five compounds (Method 2) ( Table 3) .
Fitted values of Rtransporter for uptake transporters in CP-A groups are similar to the values estimated using published mRNA data, however, fitted values for CP-B groups are different from mRNA-estimated values. With the fitted Rtransporter, the overall agreement between simulations and observations is improved (Figure 3 ) as are predictions for AUCplasma (Table 4) .
DISCUSSION
We established a PBPK model to simulate how liver cirrhosis affects the pharmacokinetics of liver transporter substrates. A major challenge is that the effect of liver cirrhosis on the in vivo transporter activity is unknown. Although previous studies have reported that liver cirrhosis may change mRNA and protein expression levels (37, 38) , it is unclear whether changes in transporter mRNA or protein expression levels due to liver disease can be directly translated into pharmacokinetics in patients.
We initially prospectively predicted the change of in vivo liver transporter activity (Rtransporter) using mRNA data. Generally tThe mean predictions can more reasonably match mean observations from CP-A than CP-B groups. This might arise if more mRNA samples in these studies were taken from CP-A patients (37, 38) . To improve prediction accuracy, transporter mRNA or protein expression data classified using the Child-Pugh system would be highly desirable in future. In addition, because the fractional contributions that transporters made to the total uptake are unknown, they are randomly generated in this analysis. This leads to additional uncertainty in predictions. Several different in vitro assays have been developed to deconvolute the contribution made by individual transporters to the overall uptake (17) . It could be useful to incorporate these data into the model once they are available. The Rtransporter value may also be predicted using experimentally determined protein expression levels, but would be only slightly less than the value estimated from mRNA data (37) . None of these compounds has been reported to be NTCP substrates, hence we did not use NTCP mRNA data. In this model, because we assumed that all parameters in Table 1 follow normal distributions and are independent with each other, the variability of the simulations may be over-predicted. However, such an assumption is validated by the fact that the approximated variability is in general comparable to the observed variability (Table 4 and Fig. 2 ).
To better describe the data, we re-estimated individual Rtransporter for CP-A and CP-B groups by fitting the observed pharmacokinetics and assuming all uptake transporters are similarly affected in the diseased conditions. As expected, the fitted value of for CP-A groups (0.78) but not CP-B groups (0.31) is similar to the mRNA-predicted values for uptake transporters (0.65 for OATP1B1, 0.73 for OATP1B3, and 0.77 for OATP2B1). ), however the fitted value for CP-B groups (0.31) is lower than these reported mRNA-predicted values. Thise top-down fitting approach provides an alternative approach method to estimated Rtransporter additional to the mRNA-predicted Rtransporter. The advantage of top-down approach is to characterize the impact of cirrhosis on the transporter activity based on the CP system, which is not available from current mRNA data. The two approaches should be further tested when data offor more compounds are available. We assumed that differences were due to liver transporter parameters, but given the very similar results with IV olmesartan and the due to the a lack of data on intestinal changes, we cannot rule out as thean alternative hypothesis given the very similar results with IV olmesartan that may be the absorption is affected to varying degrees in the diseased patients. Since the fitted
Rtransporter can better describe the in vivo data than the mRNA-predicted Rtransporter, the fitted
Rtransporter would be preferable in predicting pharmacokinetics of other compounds under cirrhosis conditions.
Additionally, liver cirrhosis has a pronounced impact on the observed pharmacokinetics of some compounds (e.g. valsartan) but not others (e.g. olmesartan), which makes it challenging to use a unique Rtransporter value to describe the change in the pharmacokinetics of all the compounds. It may be that the Child-Pugh score is not an accurate enough indicator of hepatic function, considering the score is not directly assessed on liver function. For example, a large body of conflicting literature on changes in hepatic blood flows in cirrhosis have been generated based on
Child-Pugh classification (5), indicating that given the current techniques, the Child-Pugh score cannot properly reflect the physiological changes due to cirrhosis. On the other hand, although not reflected in the mRNA data, it is also possible that the disease can more significantly affect the activity of some transporters than others. As such, because the contribution each transporter makes to the total hepatic uptake are different varies for different compounds, the liver cirrhosis cwould also have different impacts on these compounds. To test this hypothesis, we assumed that there are type-1 and type-2 uptake transporters responsible for the hepatic uptake of these compounds that have different Rtransporter values, and estimated parameters by fitting the clinical observations. With such approach, the mean simulations have improved agreement with the observations (data not shown); however, except for valsartan, the improvement is not significant.
Furthermore, such an approach is hard to apply as a prospective prediction because of the lack of information about the contributions of each transporter made to the total uptake.
In conclusion, a PBPK model for liver transporter substrates to simulate pharmacokinetics under liver cirrhosis conditions wasis established, and a meta-analysis wasis performed to obtain system dependent parameters. This model can be useful in understanding the changes of in the liver transporter activity due to cirrhosis, and may aid predicting systemic and potentially liver exposure of the liver transporter substrates under cirrhotic conditions in future.
HIGHLIGHTS
What is the current knowledge on the topic?
PBPK models have been developed to simulate pharmacokinetics of liver transporter substrates and more permeable compounds in healthy individuals. Previously developed PBPK models for individuals with liver cirrhosis assume well-stirred conditions in the liver, hence cannot be reasonably expected to describe the pharmacokinetics of transporter substrates.
What question did this study address?
This study aims at characterizing a PBPK model capable of predicting simulating the pharmacokinetics of liver transporter substrates under cirrhotic conditions, by incorporating changes in physiological and biological parameter values.
What this study adds to our knowledge?
This study presents the first mechanistic model to estimate the impact of liver cirrhosis on human pharmacokinetics of liver transporter substrates.
How this might change clinical pharmacology and therapeutics?
This model can be useful in understanding the changes in liver transporter activity due to cirrhosis, and may aid in predicting systemic and liver exposure for liver transporter substrates under cirrhotic conditions. It can be useful in the design of clinical trials and ultimately for dose adjustments in clinical practice for cirrhotic patients in the future. Table 1 . olmesartan, (C) repaglinide, (D) telmisartan, and (E) valsartan. The blue, red, and black represent the healthy individuals, patients with CP-A liver cirrhosis, and the patients with CP-B liver cirrhosis, respectively. The markers (i.e., squares, circles, and triangles) represent the observations. The solid lines represent the simulations assuming all uptake transporters are equally affected by the liver cirrhosis conditions and Rtransporter is fitted (Method 2). All simulations assume the biliary efflux transporters are equally affected by the liver cirrhosis, and the impact of cirrhosis on all transporters depends on Child-Pugh scores. Error bars indicate 95% prediction intervals estimated using observed standard deviations.
